SCHEMBL4668992

SCHEMBL4668992

Cc1ccc(C(OCCOC(c2ccccc2)c2ccc(C)cc2)c2ccccc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 3/20 0.58
SCN2A Q99250 3/20 0.58
SCN3A Q9NY46 3/20 0.58
CHRM2 P08172 3/20 0.58
ADRA2A P08913 3/20 0.58
CHRM1 P11229 3/20 0.58
SLC6A2 P23975 3/20 0.58
SLC6A4 P31645 3/20 0.58
OPRM1 P35372 3/20 0.58
DRD3 P35462 3/20 0.58
SLC6A3 Q01959 3/20 0.58
LMNA P02545 2/20 0.58
HTT P42858 2/20 0.58
CHRM4 P08173 2/20 0.58
CHRM5 P08912 2/20 0.58
CYP2D6 P10635 2/20 0.58
ADRA2B P18089 2/20 0.58
CHRM3 P20309 2/20 0.58
HRH2 P25021 2/20 0.58
HTR2A P28223 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14160236 0.92 SCN1A (0.55) SCN1ASCN2ASCN3ACHRM2ADRA2A
SCHEMBL14160114 0.92 SCN1A (0.55) SCN1ASCN2ASCN3ACHRM2ADRA2A
SCHEMBL14380432 0.91 SLC6A2 (0.46) SCN1ASCN2ASCN3ACHRM2ADRA2A
SCHEMBL14160113 0.89 SCN1A (0.51) SCN1ASCN2ASCN3ACHRM2ADRA2A
SCHEMBL9239838 0.89 SCN1A (0.51) SCN1ASCN2ASCN3ACHRM2ADRA2A
SCHEMBL4667564 0.87 SCN1A (0.65) SCN1ASCN2ASCN3ACHRM2ADRA2A
SCHEMBL28837 0.86 SLC6A2 (0.83) SCN1ASCN2ASCN3ACHRM2ADRA2A
SCHEMBL14160191 0.86 SCN1A (0.49) SCN1ASCN2ASCN3ACHRM2ADRA2A
Hydrochloric Acid SCHEMBL31097126 0.84 LMNA (0.84) SCN1ASCN2ASCN3ACHRM2ADRA2A
Iodide SCHEMBL29375153 0.84 SCN1A (0.84) SCN1ASCN2ASCN3ACHRM2ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1930308-A1 Pharmaceutical agents for the treatment of cerebral amyloidosis NYMOX CORPORATION (CA) 2008-06-11 EP disclosed
EP-0983222-B1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 2007-11-28 EP disclosed
US-6518314-B1 For treating cerebral amyloidosis; compounds that impede the transformation of dense microspheres (DMS) into amyloid NYMOX CORPORATION (CA) 2003-02-11 US disclosed
US-6130221-A ALZHEIMERS NYMOX CORPORATION (CA) 2000-10-10 US disclosed
EP-0983222-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 2000-03-08 EP disclosed
WO-1998052898-A9 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 1999-04-01 WO disclosed
WO-1998052898-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 1998-11-26 WO disclosed